Harvoni is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences, Inc. The primary component is Ledipasvir; Sofosbuvir.
| Product ID | 61958-1803_6122d2f4-19e4-4aae-89ce-bef7bfc5cb3e | 
| NDC | 61958-1803 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Harvoni | 
| Generic Name | Ledipasvir And Sofosbuvir | 
| Dosage Form | Tablet, Film Coated | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2019-08-28 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA205834 | 
| Labeler Name | Gilead Sciences, Inc | 
| Substance Name | LEDIPASVIR; SOFOSBUVIR | 
| Active Ingredient Strength | 45 mg/1; mg/1 | 
| Pharm Classes | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [EXT] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2019-08-28 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA205834 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2019-08-28 | 
| Ingredient | Strength | 
|---|---|
| LEDIPASVIR | 45 mg/1 | 
| SPL SET ID: | f4ec77e4-bae8-4db0-b3d5-bde09c5fa075 | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 61958-1801 | Harvoni | LEDIPASVIR and SOFOSBUVIR | 
| 61958-1803 | Harvoni | ledipasvir and sofosbuvir | 
| 61958-1804 | Harvoni | ledipasvir and sofosbuvir | 
| 61958-1805 | Harvoni | ledipasvir and sofosbuvir | 
| 72626-2601 | Ledipasvir and Sofosbuvir | Ledipasvir and Sofosbuvir | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  HARVONI  86095994  4608545 Live/Registered | GILEAD SCIENCES IRELAND UC 2013-10-18 |